NCT05199519View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

October 29, 2022

Study Completion Date

January 19, 2023

Conditions
CLDN18.2 Positive Solid Tumors
Interventions
DRUG

IBI345

IBI345 CAR-T cell injection by intravenous infusion

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05199519 - Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 | Biotech Hunter | Biotech Hunter